Author

J. B. Case

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 15 Immunology· 12 Biochemistry· 1 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 28 Research Focus:host-pathogen & immune response· 26 Assay:proteomics· 14 Organism:human· 13 Organism:mouse· 11 Research Focus:drug response / drug discovery· 10 Approach:statistical model· 4 Research Focus:cell type annotation· 3

Frequent Co-Authors

M. S. Diamond· 20 shared R. E. Chen· 12 shared J. E. Crowe· 8 shared S. P. J. Whelan· 7 shared Z. Liu· 7 shared D. H. Fremont· 6 shared H. Zhao· 6 shared E. S. Winkler· 5 shared

Activity by Year

2017-2024 · peak 13/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

20 shared papersMicrobiology

M. S. Diamond

Mutual co-authors in cluster

Author profile →

30 papers

Recent·Most cited

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

T. A. Desautels, K. T. Arrildt, A. T. Zemla, E. Y. Lau, F. Zhu, D. Ricci, S. Cronin, S. Zost, E. Binshtein, S. M. Scheaffer, B. Dadonaite, B. K. Petersen, T. B. Engdahl, E. Chen, L. S. Handal, , Carnahan

This paper computationally redesigns an antibody to restore potency against SARS-CoV-2 Omicron subvariants while maintaining efficacy against Delta and other variants.

Nature · May 8, 2024Peer-reviewedMicrobiology

Prototype mRNA vaccines imprint broadly neutralizing human serum antibodies after Omicron variant-matched boosting

C.-Y. Liang, S. Raju, Z. Liu, Y. Li, G. A. Arunkumar, J. B. Case, S. J. Zost, C. M. Acreman, D. C. Carvalho dos Anjos, J. S. McLellan, J. E. Crowe, S. P. J. Whelan, S. M. Elbashir, D. K. Edwards, M. S. Diamond

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

bioRxiv · Jan 3, 2024 · PreprintImmunology

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters

J. B. Case, S. M. Scheaffer, T. L. Darling, T. L. Bricker, L. J. Adams, H. H. Harastani, R. Trende, S. Sanapala, D. H. Fremont, A. C. M. Boon, M. S. Diamond

This paper evaluates the pathogenicity of SARS-CoV-2 BQ.1.1 and BA.5.5 variants in multiple rodent models, finding increased virulence in transgenic mice but not in conventional mice or hamsters.

bioRxiv · Apr 28, 2023 · PreprintMicrobiology

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins

V. K. Chonira, Y.-D. Kwon, J. Gorman, J. B. Case, Z. Ku, R. Simeon, R. G. Casner, D. R. Harris, A. S. Olia, T. Stevens, L. Shapiro, H. Boyd, Y. Tsybovsky, F. Krammer, M. Diamond, , Z. Chen

This paper reports the development of two DARPins, FSR16m and FSR22, that potently neutralize SARS-CoV-2 variants, including emerging ones, with efficacy comparable to therapeutic antibodies.

bioRxiv · May 30, 2022 · PreprintBioengineering

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

J. B. Case, S. Mackin, J. Errico, Z. Chong, E. A. Madden, B. Guarino, M. A. Schmid, K. Rosenthal, K. Ren, A. Jung, L. Droit, S. A. Handley, P. J. Halfmann, Y. Kawaoka, J. E. Crowe, , M. S. Diamond

This study evaluates the effectiveness of S309 and AZD7442 monoclonal antibodies against Omicron variants in mice, showing reduced lung infection despite decreased neutralization in vitro.

bioRxiv · Mar 17, 2022Microbiology

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice

B. Ying, S. M. Scheaffer, B. Whitener, C.-Y. Liang, O. Dmytrenko, S. Mackin, K. Wu, D. Lee, L. E. Avena, Z. Chong, J. B. Case, L. Ma, T. Kim, C. Sein, A. Woods, , M. S. Diamond

This study shows that boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibodies and protection against B.1.1.529 in mice, with the Omicron-matched booster showing slightly better outcomes.

bioRxiv · Feb 7, 2022 · PreprintMicrobiology

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

bioRxiv · Jan 12, 2022Immunology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

H. A. D. King, M. G. Joyce, I. Elakhal Naouar, A. Ahmed, C. Macedo Cincotta, C. Subra, K. K. Peachman, H. H. Hack, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, , L. L Jagodzinski

This study evaluates an adjuvanted SARS-CoV-2 RBD nanoparticle vaccine in macaques, showing robust immune responses and protection against viral challenge and variants.

bioRxiv · Apr 9, 2021Immunology

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

A. J. Schmitz, J. S. Turner, Z. Liu, I. D. Aziati, R. E. Chen, A. Joshi, T. L. Bricker, T. L. Darling, D. C. Adelsberg, W. B. Al Soussi, J. B. Case, T. Lei, M. Thapa, F. Amanat, J. A. O'Halloran, , A. H. Ellebedy

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

bioRxiv · Mar 24, 2021Immunology

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

M. G. Joyce, H. A. D. King, I. Elakhal Naouar, A. Ahmed, K. K. Peachman, C. M. Cincotta, C. Subra, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, W. C. Chang, , N. Karasavva

A SARS-CoV-2 Spike ferritin nanoparticle vaccine induces broad neutralizing antibodies and protects nonhuman primates against respiratory infection and disease.

bioRxiv · Mar 24, 2021 · PreprintImmunology

Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice

J. B. Case, R. E. Chen, L. Cao, B. Ying, E. S. Winkler, I. Goreshnik, S. Shrihari, N. M. Kafai, A. L. Bailey, X. Xie, P.-Y. Shi, R. Ravichandran, L. Carter, L. Stewart, D. Baker, M. S. Diamond

This study evaluates the protective efficacy of modified miniproteins against SARS-CoV-2 in mice, showing reduced viral burden and prevention of lung disease.

bioRxiv · Mar 1, 2021Microbiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

A. O. Hassan, F. Feldmann, H. Zhao, D. T. Curiel, A. Okumura, T.-L. Tang-Huau, J. B. Case, K. Meade-White, J. Callison, J. Lovaglio, P. W. Hanley, D. P. Scott, D. H. Fremont, H. Feldmann, M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine protects against SARS-CoV-2 infection in rhesus macaques by inducing neutralizing antibodies and T cell responses.

bioRxiv · Jan 26, 2021Microbiology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

bioRxiv · Dec 28, 2020Immunology

A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.

T. Bricker, T. Darling, A. Hassan, H. Harastani, A. Soung, X. Jiang, Y.-N. Dai, H. Zhao, L. Adams, M. Holtzman, A. Bailey, J. B. Case, D. Fremont, R. S. Klein, M. Diamond, A. Boon

This study compares intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine in hamsters, finding that intranasal immunization provides superior protection against infection and inflammation.

bioRxiv · Dec 2, 2020Microbiology

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion

S. Ding, R. Zang, J. B. Case, M. F. Gomez Castro, Z. Liu, Q. Zeng, H. Zhao, J. Son, P. W. Rothlauf, G. Hou, S. Bose, X. Wang, M. D. Vahey, T. Kirchhausen, D. H. Fremont, , S. P. J. Whelan

The paper identifies CH25H and its product 25HC as inhibitors of SARS-CoV-2 replication by blocking membrane fusion.

Proceedings of the National Academy of Sciences · Nov 25, 2020Peer-reviewedMicrobiology

The translational landscape of SARS-CoV-2 and infected cells

M. Puray-Chavez, K. Tenneti, N. Lee, Y. Wang, H. R. Vuong, Y. Liu, A. Horani, T. Huang, S. P. Gunsten, J. B. Case, W. Yang, M. S. Diamond, S. L. Brody, J. Dougherty, S. B. Kutluay

This study uses ribosome profiling to analyze SARS-CoV-2 and host mRNA translation in infected cells, finding that viral mRNAs are not more efficiently translated than host mRNAs and highlighting unique translational strategies.

bioRxiv · Nov 3, 2020 · PreprintMicrobiology

JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis

J. Son, S. Huang, Q. Zeng, T. L. Bricker, J. B. Case, J. Zhou, R. Zang, Z. Liu, X. Chang, H. H. Harastani, L. Chen, M. F. Gomez Castro, Y. Zhao, H. P. Kohio, G. Hou, , S. Ding

The paper identifies JIB-04 as a broad-spectrum antiviral that inhibits SARS-CoV-2 replication and coronavirus pathogenesis in vitro and in vivo.

bioRxiv · Sep 24, 2020Microbiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection

A. O. Hassan, N. M. Kafai, I. P. Dmitriev, J. M. Fox, B. Smith, I. B. Harvey, R. E. Chen, E. S. Winkler, A. W. Wessel, J. B. Case, E. Kashentseva, B. T. McCune, A. L. Bailey, H. Zhao, L. A. VanBlargan, , M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

bioRxiv · Jul 16, 2020 · PreprintMicrobiology

Association between neutralizing antibodies to SARS-CoV-2 and commercial serological assays

M. S. Tang, J. B. Case, C. E. Franks, R. E. Chen, N. W. Anderson, J. P. Henderson, M. S. Diamond, A. M. Gronowski, C. W. Farnsworth

This study evaluates the association between SARS-CoV-2 neutralizing antibodies and results from three commercial serological assays, finding moderate correlations and varying agreement rates.

bioRxiv · Jul 1, 2020Immunology

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells

S. Miersch, M. Ustav, Z. Li, J. B. Case, S. Ganaie, G. Matusali, F. Colavita, D. Lapa, M. R. Capobianchi, G. Novelli, J. B. Gupta, S. Jain, P. P. Pandolfi, M. S. Diamond, G. Amarasinghe, , S. S. Sidhu

The paper describes synthetic monoclonal antibodies that neutralize SARS-CoV-2 by binding to the spike protein and blocking ACE2 receptor interaction, showing potent antiviral activity.

bioRxiv · Jun 5, 2020 · PreprintBiochemistry

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

bioRxiv · May 22, 2020Immunology

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

J. B. Case, P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L.-M. Bloyet, Q. Zeng, S. Tahan, L. Droit, M. X. G. Ilagan, M. A. Tartell, G. K. Amarasinghe, J. P. Henderson, S. Miersch, , S. P. J. Whelan

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

bioRxiv · May 18, 2020Microbiology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

bioRxiv · May 12, 2020Immunology

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

Y.-L. Kang, Y.-Y. Chou, P. W. Rothlauf, Z. Liu, T. K. Soh, D. Cureton, J. B. Case, R. E. Chen, M. S. Diamond, S. P. J. Whelan, T. Kirchhausen

The paper shows that PIKfyve kinase inhibitors block infection by Zaire ebolavirus and SARS-CoV-2 by preventing viral content release.

bioRxiv · Apr 21, 2020Cell Biology

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

bioRxiv · Apr 7, 2020Immunology

Mouse hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity

J. B. Case, Y. Li, R. Elliott, X. Lu, K. W. Graepel, N. R. Sexton, E. C. Smith, S. R. Weiss, M. R. Denison

This study shows that MHV nsp14 exoribonuclease activity is necessary for resisting innate immunity by affecting viral RNA and modifications.

bioRxiv · Aug 29, 2017Microbiology

Proofreading-deficient coronaviruses adapt over long-term passage for increased fidelity and fitness without reversion of exoribonuclease-inactivating mutations

K. Graepel, X. Lu, J. B. Case, N. R. Sexton, E. C. Smith, M. R. Denison

bioRxiv · Aug 11, 2017Microbiology